Thus, the relative contribution to the cardiovascular disease burden of progressive CKD per se, hyperphosphatemia, increased FGF-23 and decreased αKlotho levels, and changes in PTH and 1,25(OH)2D need detailed clarification. The gene discussed is PTH; the disease is hyperphosphatemia.